Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin

2011154 citationsJournal Article

Authors

Hiroyuki Suzuki · Wakayama Medical University

Masaru Terai · Otsu Municipal Hospital

Hiromichi Hamada · Tokyo Women's Medical University

Takafumi Honda · Tokyo Women's Medical University

Tomohiro Suenaga · Hidaka Hospital

Takashi Takeuchi · Wakayama Medical University

Norishige Yoshikawa

Abstract

CyA treatment is considered safe and well tolerated, and a promising option for patients with refractory KD. Further investigations will be needed to clarify optimal dose, safety, and timing of CyA treatment.

Topics & Keywords

Kawasaki Disease and Coronary Complications Cardiac Structural Anomalies and Repair Coronary Artery Anomalies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Pediatric Infectious Disease Journal

Volume 30, Issue 10, pp. 871-876

DOI: 10.1097/inf.0b013e318220c3cf

Field-Weighted Citation Impact: 8.60